Inclusion:

1. The patient has clinical evidence of a peripheral nerve transection from conditions
or interventions that has or may result in motor and/or sensory impairment and
requires surgical treatment.

Exclusion:

1. Patients whose nerve repair will occur greater than 48 hours after nerve
transection.

2. Patients requiring repair of the intracranial portion of any nerve.

3. Patients requiring a nerve repair involving an allograft or conduit.

4. Patients expected to show signs of spontaneous recovery by 12 months (e.g., Bell's
palsy).

5. Patients who, in the judgement of the investigator, are not likely to demonstrate
meaningful recovery within a reasonable time frame during follow-up due to
significant muscle atrophy or other morbidity.

6. The patient has documented history or clinical signs of any condition where NTX-001
might not prove beneficial (e.g., systemic neuromuscular disease, systemic
neurological deficit, or other treatments known to affect the growth and/or
physiology of the neural and vascular system).

7. The patient has a known allergy to polyethylene glycol (PEG) or human grade
silicone.